AI-driven approaches are revolutionizing biotech research, as demonstrated by multiple studies and products. MIT researchers developed generative AI models to propose novel antibiotic structures, significantly expanding the chemical space for drug discovery. Other advances include deep learning tools for peptide design without protein structures and foundational machine learning models empowering biomarker development and clinical decision support, exemplified by Natera's proprietary AI platform.